✉news BusinessLabor first seen 20 h ago, last 20 h ago, peak #36
CSL and Alentis sign $1.6bn deal for rare kidney and liver diseases
Original: CSL and Alentis strike $1.6bn collab for rare kidney and liver diseases
Australian biotech giant CSL and Swiss-based Alentis Therapeutics have announced a collaboration worth up to $1.6 billion to develop treatments for rare kidney and liver diseases. The partnership will combine Alentis's antibody-drug conjugate platform with CSL's development and commercialisation resources, aiming to bring new therapies to patients with limited treatment options.
Why now: The unusually large deal size and focus on rare diseases with few existing therapies has drawn attention from the biotech and investor communities.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1150753